Tandem Diabetes Care Stock-Based Compensation 2012-2025 | TNDM
Tandem Diabetes Care stock-based compensation from 2012 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
| Tandem Diabetes Care Annual Stock-Based Compensation (Millions of US $) |
|
|---|---|
| 2024 | $101 |
| 2023 | $88 |
| 2022 | $85 |
| 2021 | $61 |
| 2020 | $58 |
| 2019 | $58 |
| 2018 | $24 |
| 2017 | $13 |
| 2016 | $12 |
| 2015 | $13 |
| 2014 | $15 |
| 2013 | $4 |
| 2012 | $0 |
| 2011 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $1.431B | $0.940B |
| Tandem Diabetes Care, Inc. designs, develops and markets products for people with insulin-dependent diabetes. The company's flagship product, the t:slim X2 Insulin Delivery System, or t:slim X2, is based on its proprietary technology platform. Per the company, t:slim X2 is the smallest durable insulin pump available and is also the only available pump capable of remote feature updates.Tandem Diabetes also offers t:flex insulin delivery system which includes t:flex pump, its 480-unit disposable insulin cartridge, an infusion set, t:lock cartridge and infusion set products, various pump accessories along with t:slim X2 with G5 integration. | |||